Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma

Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy

(2013) T Scullen et al.   LEUKEMIA

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction

(2013) P Storti et al.   LEUKEMIA

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy

(2012) E. Terpos et al.   ANNALS OF ONCOLOGY

A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys

(2010) Sutada Lotinun et al.   BONE

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

(2010) S. Vallet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin

(2009) Kristy M. Nicks et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity

(2008) R. S. Pearsall et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA